Regeneron narrows window for administration of COVID-19 antibodies

An independent data monitoring committee’s recommendations regarding a trial of Regeneron’s antibody cocktail in hospitalized COVID-19 patients are reinforcing the emerging picture that the optimal window to administer this class of therapies is early in infection.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Friday that it would implement the committee’s recommendation to hold enrollment of patients in the study of REGN-COV2 that require high-flow oxygen or mechanical ventilation, based on a “potential safety signal and an unfavorable benefit-risk profile.” The IDMC recommended that enrollment continue among hospitalized patients with lower oxygen needs...